Archives

Indian Journal of Pure & Applied Biosciences (IJPAB)
Year : 2020, Volume : 8, Issue : 3
First page : (317) Last page : (326)
Article doi: : http://dx.doi.org/10.18782/2582-2845.8150

Pharmacogenomic Approach to Guiding Antiplatelet Therapy after Percutaneous Coronary Intervention

Dandyala Pavan Kalyan and Nedhnuri Jyothsna*
Doctor of Pharmacy (Pharm D), Bharat Institutions of Technology, Mangalpally, Ibrahimpatanam, 501510.
*Corresponding Author E-mail: jyothsnanedhnuri@gmail.com
Received: 9.05.2020  |  Revised: 14.06.2020   |  Accepted: 17.06.2020 

 ABSTRACT

Clopidogrel, Prasugrel, Aspirin, Ticagrelor are the antiplatelet drugs which are used by the patients after percutaneous coronary intervention. Activation of these drugs is mainly by the genes and hence pharmacogenomics of these drugs is considered as the major factor for drug response. Clopidogrel alone or mostly along with aspirin as a dual therapy is preferred to reduce adverse cardiovascular events occurring after PCI. Clopidogrel, is a prodrug & its metabolism need CYP2C19 gene, which plays a key role in showing efficacy accordingly to the patients CYP2C19 alleles, and conversion of the drug to its active metabolite. CYP2C19 varies inter individual, and these variants are the reason for inter individual patient therapeutic efficacy difference. prasugrel activation is mediated by CYP450.Ticagrelor is activated by CYP3A4/5. This review presents the importance of pharmacogenomics in anti-platelet therapy, in reducing the adverse outcomes after percutaneous coronary intervention, and also it describes the CYP2C19 gene alleles variability inter-individually, and its therapeutic outcomes. Use of other antiplatelet drugs like prasugrel, ticagrelor, aspirin, in case of clopidogrel CYP2C19 poor metabolizers, their therapeutic recommendations & pharmacogenomics is also described.

Keywords: CYP2C19, Pharmacogenomics, PCI, Clopidogrel, prasugrel, Ticagrelor, Aspirin.

Full Text : PDF; Journal doi : http://dx.doi.org/10.18782

Cite this article: Kalyan, D.P., & Jyothsna, N. (2020). Pharmacogenomic Approach to Guiding Antiplatelet Therapy after Percutaneous Coronary Intervention, Ind. J. Pure App. Biosci. 8(3), 317-326. doi: http://dx.doi.org/10.18782/2582-2845.8150